0HNC Stock Overview
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
BioMarin Pharmaceutical Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$83.01 |
| 52 Week High | US$99.50 |
| 52 Week Low | US$76.29 |
| Beta | 0.32 |
| 1 Month Change | -5.65% |
| 3 Month Change | -5.60% |
| 1 Year Change | -11.77% |
| 3 Year Change | 5.07% |
| 5 Year Change | -1.01% |
| Change since IPO | -9.38% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0HNC | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 1.9% | 5.9% | 1.0% |
| 1Y | -11.8% | -26.8% | 3.0% |
Return vs Industry: 0HNC exceeded the UK Biotechs industry which returned -26.8% over the past year.
Return vs Market: 0HNC underperformed the UK Market which returned 3% over the past year.
Price Volatility
| 0HNC volatility | |
|---|---|
| 0HNC Average Weekly Movement | 4.3% |
| Biotechs Industry Average Movement | 7.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.4% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0HNC has not had significant price volatility in the past 3 months.
Volatility Over Time: 0HNC's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 3,401 | Alexander Hardy | www.biomarin.com |
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company’s commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase.
BioMarin Pharmaceutical Inc. Fundamentals Summary
| 0HNC fundamental statistics | |
|---|---|
| Market cap | US$15.65b |
| Earnings (TTM) | US$205.46m |
| Revenue (TTM) | US$2.47b |
76.2x
P/E Ratio6.3x
P/S RatioIs 0HNC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0HNC income statement (TTM) | |
|---|---|
| Revenue | US$2.47b |
| Cost of Revenue | US$1.25b |
| Gross Profit | US$1.22b |
| Other Expenses | US$1.01b |
| Earnings | US$205.46m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.08 |
| Gross Margin | 49.34% |
| Net Profit Margin | 8.31% |
| Debt/Equity Ratio | 21.4% |
How did 0HNC perform over the long term?
See historical performance and comparison